ClinicalTrials.gg
Drug

Elvitegravir clinical trials

Also written GS-9137.

studies test it
27
open now
1
in phase 3
17
first study started
2006

Counted the way a researcher would: Elvitegravir with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses elvitegravir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the elvitegravir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
27 Aug 2012 · STRIBILD · NDA 203100 (FDA, Drugs@FDA; in a combination)
European Union
24 May 2013 · Stribild · EMEA/H/C/002574 (EMA; in a combination)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Vitekta®
3
EVG
2
Elvitegravir
1

Development codes

GS-9137
2

In one entry with another drug

Given together, or one or the other

E/C/F/TAF
18

Studies by the year they started

27 studies that test it; most in 2013 (7)

Studies that test elvitegravir, by start year
YearStudies
20061
20071
20081
20111
20121
20137
20143
20157
20162
20171
20181
20241

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
6
Phase 3
17
Phase 4
3
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 22 · Other 5

Gilead Sciences (21) · Janssen Sciences Ireland UC (1) · Technical University of Munich (1) · Fundacion Clinic per a la Recerca Biomédica (1) · St Stephens Aids Trust (1) · Juan A. Arnaiz (1) · Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic (1)

Often tested with

Tested in the same studies.

Cobicistat (23) · Emtricitabine (21) · Tenofovir alafenamide (20) · Darunavir (3) · Bictegravir (2) · Atazanavir (2) · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Fumarate (2) · Emtricitabine tenofovir alafenamide (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test elvitegravir.

Studies

Open first, then newest update. How each study uses elvitegravir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 27

See all 27 studies that test elvitegravir →

Given beside what is tested · 1 — elvitegravir is usual care or a partner of the new treatment

Codes

What other systems call elvitegravir · ClinicalTrials.gg INT004902

  • MeSH (NLM) C509700elvitegravirConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 4GDQ854U53ELVITEGRAVIRConfirmed FDA, NLM, Wikidata
  • RxNorm 1306286Confirmed FDA, Wikidata
  • Wikidata Q2740966elvitegravirConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C76493ElvitegravirOne source FDA
  • DrugBank DB09101One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.